Lustberg MB, Kuderer NM, Desai A, Bergerot C, Lyman GH. Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship. Nat Rev Clin Oncol. 2023;20:527–42.

Article  PubMed  Google Scholar 

Di Maio M, Basch E, Denis F, Fallowfield LJ, Ganz PA, Howell D, et al. The role of patient-reported outcome measures in the continuum of cancer clinical care: ESMO Clinical Practice Guideline. Ann Oncol. 2022;33:878–92.

Article  PubMed  Google Scholar 

Chhabra N, Kennedy J. A review of cancer immunotherapy toxicity: immune checkpoint inhibitors. J Med Toxicol. 2021;17:411–24.

Article  PubMed  PubMed Central  Google Scholar 

Shinn EH, Broderick G, Fellman B, Johnson A, Wieland E, Moulder S, et al. Simulating time-dependent patterns of nonadherence by patients with breast cancer to adjuvant oral endocrine therapy. JCO Clin Cancer Inf. 2019;3:1–9.

Google Scholar 

Leaning D, Kaur G, Morgans AK, Ghouse R, Mirante O, Chowdhury S. Treatment landscape and burden of disease in metastatic castration-resistant prostate cancer: systematic and structured literature reviews. Front Oncol. 2023;13:1240864.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dombeck C, Swezey T, Gonzalez Sepulveda JM, Reeve BB, LeBlanc TW, Chandler D, et al. Patient perspectives on considerations, tradeoffs, and experiences with multiple myeloma treatment selection: a qualitative descriptive study. BMC Cancer. 2023;23:65.

Article  PubMed  PubMed Central  Google Scholar 

Kawahara T, Iwamoto T, Takashima I, Hanazawa R, Uemura K, Uemura Y, et al. Association of change in health-related quality of life and treatment discontinuation in metastatic breast cancer: a post hoc, exploratory analysis of two randomized clinical trials. Support Care Cancer. 2022;30:8367–75.

Article  PubMed  PubMed Central  Google Scholar 

Taarnhøj GA, Johansen C, Carus A, Dahlrot RH, Dohn LH, Hjøllund NH, et al. The iBLAD study: patient-reported outcomes in bladder cancer during oncological treatment: a multicenter national randomized controlled trial. J Patient Rep. Outcomes. 2023;7:99.

Article  PubMed  PubMed Central  Google Scholar 

Gegechkori N, Haines L, Lin JJ. Long-term and latent side effects of specific cancer types. Med Clin North Am. 2017;101:1053–73.

Article  PubMed  PubMed Central  Google Scholar 

Dai W, Feng W, Zhang Y, Wang XS, Liu Y, Pompili C, et al. Patient-reported outcome-based symptom management versus usual care after lung cancer surgery: a multicenter randomized controlled trial. J Clin Oncol. 2022;40:988–96.

Article  PubMed  PubMed Central  Google Scholar 

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2016;34:557–65.

Article  CAS  PubMed  Google Scholar 

Cardeña-Gutiérrez A, López Barahona M. Predictive biomarkers of severe immune-related adverse events with immune checkpoint inhibitors: prevention, underlying causes, intensity, and consequences. Front Med (Lausanne). 2022;9:908752.

Article  PubMed  Google Scholar 

Johannet P, Liu W, Fenyo D, Wind-Rotolo M, Krogsgaard M, Mehnert JM, et al. Baseline serum autoantibody signatures predict recurrence and toxicity in melanoma patients receiving adjuvant immune checkpoint blockade. Clin Cancer Res. 2022;28:4121–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Olsson Ladjevardi C, Koliadi A, Rydén V, Inan El-Naggar A, Digkas E, Valachis A, et al. Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study. Cancer Med. 2023;12:13217–24.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rogado J, Sánchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Leví A, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019;109:21–27.

Article  CAS  PubMed  Google Scholar 

Minasian LM, O’Mara A, Mitchell SA. Clinician and patient reporting of symptomatic adverse events in cancer clinical trials: using CTCAE and PRO-CTCAE(®) to provide two distinct and complementary perspectives. Patient Relat Outcome Meas. 2022;13:249–58.

Article  PubMed  PubMed Central  Google Scholar 

Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2022;171:103575.

Article  PubMed  Google Scholar 

Yeo HY, Liew AC, Chan SJ, Anwar M, Han CH, Marra CA. Understanding patient preferences regarding the important determinants of breast cancer treatment: A narrative scoping review. Patient Prefer Adherence. 2023;17:2679–706.

Article  PubMed  PubMed Central  Google Scholar 

European Federation of Pharmaceutical Industries and Associations (EFPIA). Improving the understanding, acceptance and use of oncology–relevant endpoints in HTA body / payer decision-making. 2023. https://www.efpia.eu/news-events/the-efpia-view/statements-press-releases/improving-the-understanding-acceptance-and-use-of-oncology-relevant-endpoints-in-hta-body-payer-decision-making.

Fameli A, Paulsson T, Altimari S, Gutierrez B, Cimen A, Nelsen L et al. Looking Beyond Survival Data. How Should We Assess Innovation in Oncology Reimbursement Decision Making. 2023. https://www.ispor.org/publications/journals/value-outcomes-spotlight/vos-archives/issue/view/looking-beyond-survival-data-in-oncology-reimbursement-decisions/looking-beyond-survival-data-how-should-we-assess-innovation-in-oncology-reimbursement-decision-making.

Bullen A, Ryan M, Ennis H, Gray E, Loría-Rebolledo LE, McIntyre M, et al. Trade-offs between overall survival and side effects in the treatment of metastatic breast cancer: eliciting preferences of patients with primary and metastatic breast cancer using a discrete choice experiment. BMJ Open. 2024;14:e076798.

Article  PubMed  PubMed Central  Google Scholar 

Gupta A, Nshuti L, Grewal US, Sedhom R, Check DK, Parsons HM, et al. Financial burden of drugs prescribed for cancer-associated symptoms. JCO Oncol Pr. 2022;18:140–7.

Article  Google Scholar 

Giap F, Chino F. What oncologists must account for: the financial burden of cancer-associated symptom relief. JCO Oncol Pr. 2022;18:106–8.

Article  Google Scholar 

Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. Pharmacoeconomics. 2013;31:753–66.

Article  PubMed  Google Scholar 

Peipert JD, Zhao F, Lee JW, Shen SE, Ip E, O’Connell N, et al. Patient-reported adverse events and early treatment discontinuation among patients with multiple myeloma. JAMA Netw Open. 2024;7:e243854.

Article  PubMed  PubMed Central  Google Scholar 

Feng C, Guo Y, Zhang X, Lv C, Li X, Li X. Omni-media health education combined with nanodrug therapy on the creation of gastrointestinal microenvironment and the improvement of treatment compliance in patients with gastrointestinal tumors. Prev Med. 2023;173:107567.

Article  PubMed  Google Scholar 

Lambert SD, Duncan LR, Culos-Reed SN, Hallward L, Higano CS, Loban E, et al. Feasibility, acceptability, and clinical significance of a Dyadic, web-based, Psychosocial and Physical Activity Self-Management Program (TEMPO) tailored to the needs of men with prostate cancer and their caregivers: a multi-center randomized pilot trial. Curr Oncol. 2022;29:785–804.

Article  PubMed  PubMed Central  Google Scholar 

Park HR, Kang HS, Kim SH, Singh-Carlson S. Effect of a smart pill bottle reminder intervention on medication adherence, self-efficacy, and depression in breast cancer survivors. Cancer Nurs. 2022;45:E874–E882.

Article  PubMed  Google Scholar 

Absolom K, Warrington L, Hudson E, Hewison J, Morris C, Holch P, et al. Phase III randomized controlled trial of eRAPID: EHealth intervention during chemotherapy. J Clin Oncol. 2021;39:734–47.

Article  CAS  PubMed  Google Scholar 

Maguire R, McCann L, Kotronoulas G, Kearney N, Ream E, Armes J, et al. Real time remote symptom monitoring during chemotherapy for cancer: European multicentre randomised controlled trial (eSMART). BMJ. 2021;374:n1647.

Article  PubMed  PubMed Central  Google Scholar 

Fjell M, Langius-Eklöf A, Nilsson M, Wengström Y, Sundberg K. Reduced symptom burden with the support of an interactive app during neoadjuvant chemotherapy for breast cancer – A randomized controlled trial. Breast. 2020;51:85–93.

Article  PubMed  PubMed Central  Google Scholar 

National Institute for Health and Care Excellence (NICE). Critical appraisal of the relevant clinical effectiveness evidence [Internet]. London: National Institute for Health and Care Excellence; [cited 2025 Mar 17]. Available from: National Institute for Health and Care Excellence (NICE). Critical appraisal of the relevant clinical effectiveness evidence [Internet]. London: National Institute for Health and Care Excellence; [cited 2025 Mar 17]. Available from: [2 Clinical effectiveness | Single technology appraisal and highly specialised technologies evaluation: User guide for company evidence submission template | Guidance | NICE.